Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development ALS vaccine is targeting the most common genetic ALS variant 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene BILTHOVEN, Netherlands and MUNICH, July 6, 2022 /PRNewswire/ --...
